Yulia Slavina

NeuroPace Inc unveils NAUTILUS Study findings on neuromodulation for drug-resistant IGE

NeuroPace Inc unveils NAUTILUS Study findings on neuromodulation for drug-resistant IGE
NeuroPace Inc unveils NAUTILUS Study data

NeuroPace Inc is drawing attention to the latest results from its NAUTILUS Study, the first randomized trial to evaluate neuromodulation therapy for patients with drug-resistant idiopathic generalized epilepsy (IGE).

The company encourages attendees to join Dr. Martha Morrell's presentation at the 2026 AAN Annual Meeting, where she will deliver key insights and data from the study. This breakthrough marks a major development in treatment options for individuals living with refractory IGE, potentially paving the way for new clinical approaches.

NeuroPace has previously encouraged individuals with uncontrolled seizures to assess their compatibility with the RNS System through an online quiz. The company continues to focus on expanding neuromodulation options for patients with drug-resistant epilepsy. These efforts frame the context for NeuroPace's latest developments announced at the AAN Annual Meeting.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.